| Labcorp Oncology

November 2022

Poster

Pan Solid Tumor Identification of NRG1 Fusions Utilizing RNA Sequencing Identifies Diverse Fusion Partners and Highlights a Lack of Co occurring Oncogenic Driver Alterations.

Event: AMP 2022

June 2, 2022

LAG3 transcriptomic expression correlates with high levels of PD 1, PD L1, PD L2, and CTLA 4 checkpoints and with high tumor mutational burden across cancers

June 2022

Poster

LAG3 transcriptomic expression correlates with high levels of PD 1, PD L1, PD L2, and CTLA 4 checkpoints and with high tumor mut ational burden across cancers

Event: ASCO 2022

June 2, 2022

Mutational landscape and clinical characterization of over 17000 patient samples with myeloid malignancies using real world data

June 2022

Poster

Mutational landscape and clinical characterization of over 17000 patient samples with myeloid malignancies using real world data

Event: ASCO 2022

<span>Eric M. O’Neill, PhD</span>

Eric M. O’Neill, PhD

Associate Technical Director, DNA Identification Testing, Labcorp

<span>James Kyle Farquhar, PhD</span>

James Kyle Farquhar, PhD

Consultant Laboratory Director, Office of the Chief Scientific Director

<span>Chevonne Eversley, PhD, DABMG</span>

Chevonne Eversley, PhD, DABMG

Co-Discipline Director, Molecular Genetics and Genomics, Labcorp

<span>Zahra Shajani-Yi, PhD, DABCC</span>

Zahra Shajani-Yi, PhD, DABCC

Discipline Director, Esoteric and Routine Immunoassay, Labcorp

<span>Ted Johnson</span>

Co-Discipline Director, Specimen Quality, Labcorp